NCT07413952尚未招募2 期
Efficacy and Safety of Limertinib (ASK120067) Combined With Radiotherapy as First-Line Treatment in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases: A Single-Arm, Multicenter, Prospective Phase II Study
The First Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Intracranial progression-free survival (iPFS)
研究概览
简要总结
Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients.
Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity. The potential synergistic effect of limertinib combined with radiotherapy warrants further investigation.
This prospective, multicenter, single-arm phase II study aims to evaluate the efficacy and safety of first-line limertinib combined with radiotherapy in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must voluntarily agree to participate in this study and sign a written informed consent form.
- •Patients aged 18-75 years. Patients must have histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC), staged as IV according to the 9th edition of the American Joint Committee on Cancer (AJCC) TNM staging system.
- •Histological or cytological reports issued by nationally accredited hospitals or third-party testing institutions confirming the presence of EGFR classical mutations (19Del & 21L858R).
- •ECOG PS score of 0-1, and an estimated survival of ≥3 months, as determined by the investigator.
- •Brain metastases (meningeal/parenchymal) confirmed by CT or MRI, with or without symptoms.
- •Patients must have at least one measurable lesion according to RECIST 1.1 criteria.
- •≥3 primary brain lesions, with at least one lesion ≥2 cm. Patients must not have received any prior systemic anti-cancer treatment for advanced/metastatic non-small cell lung cancer, including standard chemotherapy, biological therapy, targeted therapy, immunotherapy, or investigational drug therapy. Patients who have received adjuvant or neoadjuvant therapy (chemotherapy and/or radiotherapy) are eligible if no disease progression occurred within 6 months after completion of treatment. Patients who have received local treatment (radiotherapy or pleural perfusion therapy) are also eligible if the treated lesions are not target lesions.
- •Patients must meet the following organ function criteria:
- •Absolute neutrophil count (ANC) ≥1.5×10⁹/L. 2) Platelet count ≥100×10⁹/L. 3) Hemoglobin (HGB) ≥90 g/L. 4) Serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN). For patients with liver metastases, TBIL may be up to 3× ULN.
- •5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN. For patients with liver metastases, AST and ALT may be up to 5× ULN.
- •6) Serum creatinine (SCr) ≤1.5× ULN, or creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula).
- •Male patients with reproductive potential and female patients who may become pregnant must use highly effective contraceptive methods during the study and for 12 months after treatment discontinuation.
排除标准
- •Patients unable to confirm a diagnosis of non-small cell lung cancer (NSCLC) through histological or cytological examination.
- •Patients expected to require other systemic anti-cancer treatments outside of this study during the trial period.
- •Patients diagnosed with malignant tumors within the past 2 years, except for well-controlled cutaneous basal cell carcinoma, cervical carcinoma in situ, or ductal carcinoma in situ of the breast.
- •Patients with significant gastrointestinal diseases that may affect drug intake or absorption, including but not limited to peptic ulcer disease or inflammatory bowel disease.
- •Patients with known or suspected hypersensitivity to the study interventions (lielitinib and radiotherapy) or components of study-related preparations.
- •Patients who have previously received any epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.
- •Patients who have used strong CYP3A4 inhibitors or inducers within 7 days prior to the first dose of study drug, or who are expected to require long-term use of these medications during the trial. Additionally, patients who have used traditional Chinese medicine or preparations with anti-tumor indications within 2 weeks prior to the first dose of study drug, or who are expected to require such use during the trial, will also be excluded.
- •Patients with a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring corticosteroid treatment. Patients with acute exacerbation or progressive pulmonary symptoms at baseline, or those considered unsuitable for inclusion by the investigator due to high-risk factors for interstitial lung disease, will also be excluded.
- •Patients with significant arrhythmia (e.g., QT interval >470 ms) or heart failure (left ventricular ejection fraction <50%).
- •Pregnant or lactating women. Patients currently participating in or who have participated in other clinical trials within the past 4 weeks.
- •Patients with serious acute or chronic medical or psychiatric conditions, as determined by the investigator, that may increase the risks associated with study participation or interfere with the interpretation of study results.
研究组 & 干预措施
Limertinib Plus Radiotherapy
Experimental
干预措施: Limertinib Plus Radiotherapy (Drug)
结局指标
主要结局
Intracranial progression-free survival (iPFS)
时间窗: Up to 36 months
Intracranial progression-free survival (iPFS) is defined as the time from the initiation of study treatment to the first documented intracranial disease progression or death from any cause, whichever occurs first, as assessed by magnetic resonance imaging (MRI) according to RECIST version 1.1 criteria.
次要结局
未报告次要终点
研究者
Jiexia Zhang
Professor
The First Affiliated Hospital of Guangzhou Medical University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boosting with cobicistat2023-505700-35-00University Hospital Maastricht60
招募中
2 期
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET AmplificationNCT07322783Qingdao Central Hospital60
招募中
3 期
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)2024-516598-60-00Mirati Therapeutics Inc.196
招募中
2 期
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyNCT07375316Guangdong Association of Clinical Trials120
尚未招募
2 期
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)2024-516790-78-00Universitat Heidelberg40